Exploratory Study of a CT Radiomics Model for the Classification of Small Cell Lung Cancer and Non-small-Cell Lung Cancer

Shihe Liu¹, Shunli Liu¹, Chuanyu Zhang¹, Hualong Yu¹, Xuejun Liu¹, Yabin Hu¹, Wenjian Xu¹, Xiaoyan Tang¹ and Qing Fu²*

¹ Department of Radiology, The Affiliated Hospital of Qingdao University, Qingdao, China, ² Department of Ultrasound, The Affiliated Hospital of Qingdao University, Qingdao, China

Background: Radiomics can quantify tumor phenotypic characteristics non-invasively by applying feature algorithms to medical imaging data. In this study, we investigated the association between radiomics features and the tumor histological subtypes, and we aimed to establish a nomogram for the classification of small cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC).

Methods: This was a retrospective single center study. In total, 468 cases including 202 patients with SCLC and 266 patients with NSCLC were enrolled in our study, and were randomly divided into a training set (n = 327) and a validation set (n = 141) in a 7:3 ratio. The clinical data of the patients, including age, sex, smoking history, tumor maximum diameter, clinical stage, and serum tumor markers, were collected. All patients underwent enhanced computed tomography (CT) scans, and all lesions were pathologically confirmed. A radiomics signature was generated from the training set using the least absolute shrinkage and selection operator algorithm. Independent risk factors were identified by multivariate logistic regression analysis, and a radiomics nomogram based on the radiomics signature and clinical features was constructed. The capability of the nomogram was evaluated in the training set and validated in the validation set.

Results: Fourteen of 396 radiomics parameters were screened as important factors for establishing the radiomics model. The radiomics signature performed well in differentiating SCLC and NSCLC, with an area under the curve (AUC) of 0.86 (95% CI: 0.82–0.90) in the training set and 0.82 (95% CI: 0.75–0.89) in the validation set. The radiomics nomogram had better predictive performance [AUC = 0.94 (95% CI: 0.90–0.98) in the validation set] than the clinical model [AUC = 0.86 (95% CI: 0.80–0.93)] and the radiomics signature [AUC = 0.82 (95% CI: 0.75–0.89)], and the accuracy was 86.2% (95% CI: 0.79–0.92) in the validation set.

Conclusion: The enhanced CT radiomics signature performed well in the classification of SCLC and NSCLC. The nomogram based on the radiomics signature and clinical factors has better diagnostic performance for the classification of SCLC and NSCLC than the simple application of the radiomics signature.

Keywords: quantitative imaging, lung cancer histology, tomography, X ray, radiomics, classification
INTRODUCTION

Lung cancer is the most common malignant tumor in the world, ranking first in cancer-related deaths (1, 2). One study showed that the annual survival rate of lung cancer patients after early diagnosis and treatment can be increased from 14 to 49% (3). There are two main types of lung cancer: small cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC) (4). SCLC is highly malignant and sensitive to radiotherapy and chemotherapy (5); NSCLC is relatively less malignant, and the probability of early metastasis is relatively low. It is not as sensitive to chemoradiotherapy as SCLC (6). Treatment for SCLC is mainly based on chemotherapy and radiotherapy (5), whereas treatment for NSCLC is mainly based on surgical resection or surgery plus radiotherapy and chemotherapy (5, 7, 8). Histological classification can help doctors determine the best treatment plan and strategy for lung cancer patients (9, 10). Currently, the most widely used methods to obtain pathological tissue are tracheoscopy and computed tomography (CT)-guided percutaneous lung biopsy (11–14). However, both of these technologies are invasive, with certain risks and high costs (15, 16). In addition, for a certain proportion of lung cancer cases adjacent to the mediastinum, aorta, and other large blood vessels, CT-guided biopsy is highly risky and difficult (16), while bronchoscopy has a low success rate in the extraction of lesions below grade 5 of the bronchus (17). Therefore, thoracic surgeons and pulmonary oncologists hope to find a non-invasive and cost-effective alternative. In recent years, a large number of basic studies have suggested that radiomics provides promising opportunities in this regard. It assesses the tumor tissue characteristics non-invasively. Furthermore, radiomics is relatively cost-effective and has been used for oncological diagnosis, staging, and treatment guidance with high accuracy (18–22).

A limited number of studies have investigated the association of radiomic features and NSCLC tumor histology (23–28). It is believed that imaging features can independently predict the histological subtypes of lesions and provide a basis for the formulation and modification of clinical treatment plans. However, because no clinical parameters were added, the prediction efficiency of these models was still not as expected (23–28). Therefore, this study aimed to establish a prediction model based on enhanced CT images and clinical features for the histological classification of SCLC and NSCLC and to preliminarily explore the clinical application value of this model.

MATERIALS AND METHODS

Data Cohort

The protocol was approved by the Institutional Review Board of the Affiliated Hospital of Qingdao University. The need for informed consent was waived by the Institutional Review Board. A cohort of consecutive 3,971 patients with lung cancer who were confirmed by biopsy or surgery between January 2014 and June 2018 was identified for this retrospective study.

The inclusion criteria were as follows: (1) pathological confirmation of lung cancers based on the histological examination of surgical resection or biopsy specimens; and (2) availability of dual-phase contrast-enhanced CT before treatment.

The exclusion criteria were as follows: (1) no enhanced CT examination in our hospital (n = 1,537); (2) no thin-layer recombination images or poor image quality (n = 528); (3) patients with incomplete clinical data (n = 864); (4) patients who received previous treatment (e.g., radiotherapy, chemotherapy) before surgery (n = 423); (5) difficulty in precisely drawing the regions of interest (ROIs) due to small size (long diameter < 1 cm) (n = 166); and (6) patients with a history of other primary malignancies (n = 85).

Finally, a total of 468 cases (202 patients with SCLC and 266 patients with NSCLC) were enrolled in our study (Figure 1).

The clinical data included age, sex, smoking history, clinical stage, maximum tumor diameter, and serum tumor markers [serum gastrin-releasing peptide precursor (ProGRP), squamous cell carcinoma antigen (SCCA), carcinoembryonic antigen (CEA), neuron specific enolase (NSE), and cytokeratin 19 fragment (cYFRA21-1)]. According to previous studies (29, 30), the correlation between a small amount of smoking or occasional smoking and lung cancer remains uncertain, therefore, the smoking history in this study was defined as those who had a history of smoking for more than 1 year and smoked more than 20 cigarettes per day on average based on the WHO definition of heavy smokers.

CT Image Acquisition

The radiomics workflow is displayed in Figure 2. Contrast-enhanced CT images were acquired at our hospital using either a SOMATOM (Siemens Medical Systems, Germany) scanner or a Brilliance iCT 256 (Philips Healthcare, Netherlands) scanner. The CT scanning project in our hospital was based on our country’s conventional technical specifications for chest-enhanced CT scans. The scanning parameters used in this study were as follows: tube voltage, 120 kVp; detector collimation, 64 × 0.6 and 128 × 0.625 mm; pixel size, 512 × 512; slice interval, 0 mm; slice thickness, 5 mm; and reconstructed section thickness, 1 mm. Contrast-enhanced CT images were acquired after the injection of 1.0 mL/kg contrast material (iohexol injection, 300 mg/mL, Beilu Pharmaceutical Co., Ltd., Beijing, China) into the antecubital vein at a rate of 3.0–3.5 mL/s using a power injector (Ulrich CT Plus 150, Ulrich Medical), followed by a saline flush (20 mL). All patients in our cohort were scanned 25 and 70 s after injection of the contrast agent to obtain the images in the arterial phase and venous phase, respectively.

Pathological Evaluation

According to the World Health Organization (WHO) classification of lung tumors (2015 version), all histopathological sections were retrospectively analyzed by two pathologists (WHW and JGW, with 13 and 11 years of experience, respectively, in pathological diagnosis of lung cancer). In cases of disagreement, the third pathologist (ZMW, with 19 years of experience in pathological diagnosis of lung cancer) made the final decision. All pathologists were blinded to the clinicopathological information.
CT Radiomics Feature Extraction
Lesion outlining on CT images was performed using ITK-SNAP software (http://www.itksnap.org, version: 3.8.0, USA). The arterial and venous images were analyzed following the same procedure. One radiologist (YBH) with 8 years of experience in lung imaging interpreted CT images and outlined the edge of the target lesion. One week later, another radiologist (HLY) with 11 years of experience in lung imaging performed ROI segmentation and feature extraction independently. The two radiologists were blinded to the clinicopathological information. The lung cancer lesions were manually identified by a radiologist and confirmed by another radiologist, who were both blinded to the clinicopathological information of the patients. Each ROI was manually outlined along the margin of the lesion on the largest slice. The original images were normalized before feature extraction. Commercial software (Analysis Kit 1.0.3; GE Healthcare, China) was used to extract features. A total of 396 quantified features were extracted automatically from the delineated ROIs with four categories of radiomics features, including 10 Haralick features, 42 histograms, 9 form factors, 11 gray-level size zone matrix (GLSZM) features, 60 gray-level run-length matrix (GLRLM) features with an offset of 1/4/7, and 48 gray-level cooccurrence matrix (GLCM) features with an offset of 1/4/7.

Development of the Radiomics Signature and Radiomics Nomogram
To reduce overfitting and select the most informative clinical and radiomics features to develop a predictive model, the least absolute shrinkage and selection operator (lasso) regression method was utilized to select the most valuable features from the primary datasets. These radiomics features with non-zero coefficients were thus selected, and radiomics scores (Rad-scores) were calculated for each patient using a linear combination of the selected features that were weighted by their respective coefficients. The diagnostic performance of the radiomics signature was quantified by the area under the receiver operating
characteristic (ROC) curve (AUC) in the primary cohort and then validated in the validation cohort.

For validation, we evaluated the Rad-score difference between the two classes and used the “compare the mean between two groups” method to calculate the sample size of the validation cohorts, which satisfied the statistical power of more than 0.8. In our study, the difference in Rad-score between the two groups was 1.5. The necessary sample size of the validation cohort was 44 and we used 141 cases to validate the model. We did not retrain the model in the validation cohort. We used the cutoff obtained from the training cohort to calculate the metrics in the validation cohort.

Clinical risk factors for SCLC, including sex, age, tumor maximum diameter, smoking, clinical stage and tumor marker indicators, were first assessed in the primary cohort by using correlation analysis and multiple logistic regression analysis. Clinical features with \( P < 0.05 \) and the radiomics signature were applied to develop a diagnostic model for distinguishing SCLC and NSCLC by using multivariate logistic regression in the primary cohort. Backward stepwise selection was applied using a likelihood ratio test with Akaike’s information criterion as the stopping rule. To provide clinicians with a quantitative tool to predict the pathological type of lung cancer, a radiomics nomogram was built on the basis of the multivariable logistic analysis in the primary cohort. Rad-scores were also calculated in the validation set by using the algorithm built with the training set.

Validation and Assessment of the Radiomics Nomogram

The diagnostic value of the radiomics nomogram was assessed in both the training and validation cohorts regarding discrimination, calibration and clinical value. The discrimination performance of the radiomics nomogram was quantified using ROC curves and AUC values. Calibration curves were plotted to evaluate the goodness-of-fit of the radiomics nomogram, and the Hosmer-Lemeshow test was also performed (a non-significant test statistic implies that the model calibrates well). To estimate whether the nomogram is sufficiently robust for clinical use, decision curve analysis (DCA) was applied to calculate the net benefits for a range of threshold probabilities in both the training and validation sets. The net benefit was assessed by calculating the difference between the true-positive rate and weighted false-positive rate across different threshold probabilities in the validation set.

Statistical Analysis

The differences in continuous variables were analyzed by an independent \( t \)-test. Fisher’s exact test or the chi-square test was used for categorical variables. The diagnostic performance of the multivariate models was evaluated using ROC analysis and AUC values. The diagnostic sensitivity, specificity, accuracy, positive likelihood ratio, and negative likelihood ratio were also calculated.

The intra-class correlation coefficient (ICC) was calculated to evaluate the interobserver variability of radiomics feature extraction. Radiomics features with ICC values no lower than 0.75 were regarded as highly reproducible features.

All statistical analyses were performed using R statistical software (http://www.R-project.org, version 3.4.4). Lasso regression was performed using the “glmnet” package. Multivariate logistic regression, nomogram construction, and calibration plot construction were performed using the “rms” package. DCA was performed using the “dca.r” function. ROC curves were drawn and analyzed using the “proc” package. A two-tailed \( P < 0.05 \) was considered statistically significant.

RESULTS

Comparison of Clinical Factors Between SCLC and NSCLC Patients

The results showed that there was a statistically significant difference in the proportion of smoking between SCLC and NSCLC patients (\( P < 0.001 \)), and there was no statistically significant difference in sex, age, tumor maximum diameter, or preoperative clinical stage (\( P > 0.05 \)), as shown in Table 1. Comparing the clinical data and clinical stages of the training and validation sets, the results showed that there was no significant difference in age, sex, preoperative clinical stage, tumor maximum diameter, or pathological stage between the training set and the validation set (\( P > 0.05 \)), as shown in Table 2.

### Table 1 | Comparison of Clinical Factors and Clinical Stages between SCLC and NSCLC Patients (Number)

| Clinical Features | SCLC (n = 202) | NSCLC (n = 266) | p-value | t-value or \( \chi^2 \)-value |
|-------------------|----------------|----------------|----------|-----------------------------|
| Sex               |                |                |          |                             |
| Male              | 152 (75.2%)    | 188 (70.7%)    | 0.272    | 1.207*                      |
| Female            | 50 (24.8%)     | 78 (29.3%)     |          |                             |
| Age (years)       | 61.6 ± 9.3    | 62.3 ± 9.82    | 0.401    | 0.840                       |
| Smoking           |                |                |          |                             |
| Yes               | 160 (79.2%)    | 162 (60.9%)    | <0.001   | 17.924*                     |
| No                | 42 (20.8%)     | 104 (39.1%)    |          |                             |
| Clinical Stage    |                |                |          |                             |
| Early (I, II)     | 68 (33.7%)     | 101 (40.0%)    | 0.337    | 0.923*                      |
| Late (III, IV)    | 134 (66.3%)    | 165 (60.0%)    |          |                             |

* \( \chi^2 \)-value (continuous variables were analyzed by the t-test and categorical variables were analyzed by the chi-square test).
The Predictive Efficacy of the Radiomics Signature for the Classification of SCLC and NSCLC

Through the reproducibility evaluation (inter- and intra datasets with a consistency coefficient >0.75) and the removal of highly correlated features (correlation coefficient >0.6), 14 features were screened out using lasso logistic regression, as shown in Figures 3A–C. Figure 4 shows the Rad-scores for each patient in the training and validation sets.

Predictive Efficacy of the Radiomics Signature and the Radiomics Nomogram

The radiomics signature established in this study has good ability to distinguish and predict the pathological types of SCLC and NSCLC. The AUC of the prediction model in the training set was 0.86 (95% CI: 0.82–0.90), and the AUC in the validation set was 0.82 (95% CI: 0.75–0.89), as shown in Figures 5A,B.

Clinical factors found to be significantly associated with the classification of SCLC and NSCLC by univariate analysis are presented in Table 3. They include smoking and serum NSE and cYFRA21-1 values (P < 0.05 each). A clinical model was built based on the results of the multivariate logistic regression analysis of clinical variables. The results of multivariate logistic regression analysis suggested that smoking, serum NSE and cYFRA21-1 and Rad-score were independent predictors for the classification of SCLC and NSCLC (Table 4), with AUCs of 0.86 and 0.82, respectively. A radiomics nomogram incorporating the predictors, including smoking, NSE, cYFRA21-1 and Rad-score, was constructed (Figure 6).

The calibration curve shows good agreement between the predicted probability of the nomogram and the actual probability (Figure 7). Compared with the results of the radiomics signature and clinical model, the nomogram has better prediction efficiency (Table 5 and Figure 8). In the training and validation sets, the AUC values were 0.93 (95% CI: 0.90–0.96) and 0.94 (95% CI: 0.90–0.98), and the accuracy was 0.85 (95% CI: 0.80–0.88) and 0.86 (95% CI: 0.79–0.92), respectively. The DCA for the radiomics nomogram is displayed in Figure 9, which shows that the radiomics nomogram is superior to the clinical model regarding the “treat all” vs. “treat none” strategies when the threshold probability is within the 0.1–1.0 range.

DISCUSSION

In traditional single-energy CT imaging, tumors are assessed based on attenuation, morphology, and invasiveness. The effect of treatment is assessed based on changes in solid tumor volume and density (31). However, it is usually not possible to determine the pathological type of tumors based only on tumor morphology. Radiomics focuses on extracting a large number of quantitative imaging features, which can provide a detailed and comprehensive characterization of the tumor phenotype, and uses statistics and/or machine learning methods to screen the most valuable radiomics characteristics to analyze clinical information for the diagnosis and treatment of tumors (32–34). In recent years, a large number of basic studies have suggested that radiomics could evaluate tumor tissue characteristics in a non-invasive manner with high predictive accuracy (35, 36).

In this study, we observed 14 radiomics features with a significant association with the histological subtypes of lung cancer. The radiomics model established in this study has good predictive performance for the pathological classification of SCLC and NSCLC. The AUCs of the radiomics signature predictive model in the training set and the validation set were 0.86 and 0.82, respectively.

Furthermore, we found that clinical features including smoking status, NSE and cYFRA21 had potential ability to differentiate between SCLC and NSCLC. We built a radiomics nomogram including smoking status, NSE, cYFRA21, and Rad-score for individualized SCLC and NSCLC prediction. The AUC value of the radiomics nomogram in the validation set was 0.94, indicating that it has better predictive performance than the clinical model (AUC = 0.86) and the radiomics signature (AUC = 0.82). The accuracy, specificity and sensitivity were also improved, and the results of the validation set were as follows: accuracy: 86.2%; sensitivity: 84.7%; and specificity: 87.3%. The nomogram visualized the radiomic signature and clinical prediction factors into an easy-to-use tool for the individualized prediction of SCLC and NSCLC. In addition, calibration curves were constructed to indicate the performance of the radiomics nomogram for the classification of SCLC and NSCLC. The curves demonstrated good agreement between the predicted and observed values in the training and validation.

### Table 2

| Set               | Number of cases | Age (years) | Sex | Smoking | Clinical staging | Tumor maximum diameter (cm) | Pathological type |
|-------------------|-----------------|-------------|-----|---------|------------------|-----------------------------|------------------|
|                   |                 | M           | F               | I | II | III | IV | | Small cell lung cancer | Squamous cell carcinoma | Adenocarcinoma | Large cell lung cancer |
| Training set      | 327             | 62.2 ± 9.60 | 232            | 95 | 223 | 12 | 112 | 95 | 108 | 4.77 ± 2.42 | 141 | 70 | 70 | 46 |
| Validation set    | 141             | 61.5 ± 9.33 | 108            | 33 | 97  | 6  | 45  | 46 | 44  | 4.80 ± 2.53 | 61  | 30 | 30 | 20 |
| t or χ²           | 0.730           | 1.581*      | 0.016          | 0.766* | 0.114 | 0.003* | | | | | | | |
| p-value           | 0.466           | 0.209       | 0.898          | 0.858 | 0.909 | 1 |

*χ²-value (continuous variables were analyzed by the t-test and categorical variables were analyzed by the chi-square test).
FIGURE 3 | (A) The binomial deviation from the lasso regression cross-validation model is plotted as a log ($\lambda$) function by using the 10-fold cross-validation method. The y-axis represents binomial deviation, the lower (Continued) x-axis represents log ($\lambda$), and the numbers above the x-axis represent the average number of predictive variables. The red dot represents the average deviation value of each model with a given $\lambda$, while the vertical bar of the red dot represents the upper and lower limit values of the deviation. The vertical dotted line represents the log ($\lambda$) value corresponding to the best $\lambda$ value; the selection standard is the minimum standard. By adjusting different parameters ($\lambda$), the binomial deviation of the model is minimized, and the feature datasets with the best performance are selected. (B) Plots the coefficients of the log ($\lambda$) function. The $\lambda$ value is the smallest at the dotted line. Select the coefficient that is not 0 here as the coefficient of the last reserved feature. (C) The y-axis shows the 14 feature names with non-zero coefficients retained at the minimum value of $\lambda$, and the x-axis shows their total coefficients in the lasso Cox analysis. The larger the coefficients are, the greater the predictive significance.

sets. In this study, central small cell lung cancer accounted for 67.3% of all small cell lung cancer cases, and in the non-small cell lung cancer group, the proportion of central NSCLCs was 60.5%. There was no significant difference between the two groups ($p = 0.13$). The previous reports ($37$) showed that central small-cell lung cancer accounted for $\sim$90–95% of all small-cell lung cancer cases. In this study, central small-cell lung cancer accounted for a relatively low proportion. The possible reason is that some of the cases included in this study were surgical cases, while most small-cell lung cancers cannot be surgically removed, so the location results of lung cancer in this study may not be representative of the general population. Thus, this study did not introduce location as a feature of the study.

In 2002, Kido et al. ($38$) analyzed 70 cases of bronchial carcinoma (61 cases of adenocarcinoma and 9 cases of squamous cell carcinoma) by the fractal method. The results showed that the three-dimensional classification obtained from grayscale images was helpful in distinguishing adenocarcinoma from squamous cell carcinoma. Wu et al. ($23$) analyzed the relationship between radiomics features and the subtypes (adenocarcinoma and squamous cell carcinoma) of lung cancer. A total of 440 features were extracted in the study. After multivariate analysis and feature selection, the five most relevant features were applied, and the diagnostic efficiency (AUC) of the model was 0.72. Junior et al. ($25$) found that the AUCs of the training group and the validation group were 0.71 and 0.81, respectively, when the radiomics features of lung cancer CT images were used to distinguish adenocarcinoma, squamous cell carcinoma and large cell carcinoma, which indicated that the radiomics method had great potential in the diagnosis of the histopathological subtypes of lung cancer. One study in 2018 ($26$) showed that the radiomics signature established by lasso logistic regression model can distinguish adenocarcinoma and squamous carcinoma well. The AUCs of the training set and validation set were 0.905 and 0.893, respectively. Linning et al. ($27, 28$) found that the use of a radiomics approach for classifying the histological subtypes of lung cancer demonstrated potential for differentiating AD and SCC, as well as AD and SCLC; however, the approach showed relatively low performance in classifying SCC and SCLC. For classifying AD and SCC, AD and SCLC, and SCC and SCLC, the AUCs were 0.801, 0.857, and 0.657 (non-enhanced); 0.834,
FIGURE 4 | The Rad-score of each patient in the training set (A) and validation set (B). The Rad-score is classified according to the threshold value. The Wilcoxon test was used to assess the difference between the two sets.

FIGURE 5 | Radiomics signature ROC curves used to assess predictive performance. (A) The AUC of the training set is 0.86. (B) The AUC of the validation set is 0.82.
0.855, and 0.619 (arterial phase); and 0.864, 0.864, and 0.664 (venous phase), respectively. According to their studies (27, 28), the prediction efficiency of the model based on enhanced CT was better than or equal to that based on non-contrast CT imaging, and non-contrast CT was not available in many cases due to the lack of thin-layer recombination images in our study. As a result, non-contrast CT was not used to extract CT radiomics features, and only dual-phase enhanced CT was independently analyzed to establish predictive models in our study. The AUCs of our model in the training and validation sets were 0.93 and 0.94, respectively, which were higher than the previous results. One of the possible reasons may be that our study included a larger sample size, and the other may be that we added clinically relevant prediction parameters, which may make our results more comprehensive and accurate. In our study, we included samples of all major lung cancer subtypes, including SCLC, adenocarcinoma, squamous cell carcinoma, and large cell lung cancer. Our findings suggest that some robust radiomics features have great potential for the classification of SCLC and NSCLC. The established radiomics nomogram has a better prediction ability for the classification of SCLC and NSCLC, which require different treatment options. We believe that our work may serve as a promising diagnostic tool for the classification of SCLC and NSCLC in a non-invasive manner, allowing clinicians to select the appropriate treatment plan for lung cancer patients.

This study has certain limitations. First, this study used only contrast-enhanced CT image features and did not compare the classification performance with models established by positron emission tomography (PET) imaging or other imaging modalities such as non-contrast CT. These all need further study. Second, this study is a retrospective study, and there may be bias in case selection. Extracting texture features from artificially segmented data makes it difficult to remove small blood vessels and bronchi in nodules or masses, which may affect the accuracy of certain features. Third, this study is a single-center retrospective study. Although this study used a cross-validation method and the amount of data was repeatedly calculated and verified, the number of cases in this study was relatively small and could not meet the requirements of a large number of samples, which may lead to instability. In the future, we

TABLE 3 | Positive results of univariate analysis for the classification of SCLC and NSCLC.

| Variables   | OR (95% CI)     | P-value |
|-------------|-----------------|---------|
| Smoking     | 2.35 (1.42–3.97) | <0.01   |
| Serum       | 1.00 (1.00–1.00) | <0.01   |
| NSE         | 1.03 (1.02–1.04) | <0.01   |
| cYFRA21     | 0.93 (0.88–0.98) | 0.01    |

TABLE 4 | Positive results of multivariate logistic regression analysis for the classification of SCLC and NSCLC.

| Variables      | OR (95% CI)     | P-value |
|----------------|-----------------|---------|
| (Intercept)    | 0.42 (0.21–0.82) | 0.01    |
| Smoking        | 1.14 (0.57–2.28) | 0.71    |
| Serum          | 1.00 (1.00–1.00) | <0.01   |
| NSE            | 1.01 (1.00–1.02) | 0.07    |
| cYFRA21        | 0.97 (0.91–1.02) | 0.35    |
| Rad-score      | 4.00 (2.55–6.70) | <0.01   |

FIGURE 6 | Radiomics nomogram for predicting SCLC and NSCLC.
FIGURE 7 | Calibration curves of the radiomics nomogram in the training set (A) and validation set (B). The calibration curves show the calibration of the nomogram in terms of agreement between the predicted probability of SCLC and pathological findings. The 45° blue line indicates perfect prediction, and the dotted lines indicate the predictive performance of the nomogram. The closer the dotted line fit to the ideal line, the better the predictive accuracy of the nomogram.

TABLE 5 | Predictive ability of the radiomics nomogram, radiomics signature, and clinical model for the classification of SCLC and NSCLC.

| Variables              | AUC   | (95% CI) | Accuracy | Sensitivity | Specificity |
|------------------------|-------|----------|----------|-------------|-------------|
| Clinical model         | Train | 0.88     | (0.85–0.92) | 0.84        | 0.84        | 0.84        |
|                        | Test  | 0.86     | (0.80–0.93) | 0.84        | 0.83        | 0.85        |
| Radiomics signature    | Train | 0.86     | (0.82–0.90) | 0.75        | 0.65        | 0.87        |
|                        | Test  | 0.82     | (0.75–0.89) | 0.76        | 0.67        | 0.88        |
| Radiomics nomogram     | Train | 0.90     | (0.90–0.96) | 0.85        | 0.80        | 0.88        |
|                        | Test  | 0.94     | (0.90–0.98) | 0.86        | 0.85        | 0.87        |

FIGURE 8 | The AUC was used to estimate the predictive power of different models (A: training set; B: validation set). The radiomics signature and clinical model can be used for the classification of SCLC and NSCLC. In the validation set, the predictive ability of the nomogram (red, AUC = 0.94) was better than that of the clinical model (green, AUC = 0.86). The addition of clinical features improves the prediction efficiency of the radiomics signature.
Liu et al. Classification of Lung Cancer Histology by Radiomics

FIGURE 9 | DCA for the radiomics nomogram. The y-axis shows the net benefit. The red line represents the radiomics nomogram. The blue line indicates the hypothesis that all patients had small cell lung cancer. The black line represents the hypothesis that no patients had small cell lung cancer. The x-axis shows the threshold probability, which is where the expected benefit of treatment is equal to the expected benefit of not undergoing treatment. The decision curves indicate that when the threshold probability is between 0.1 and 1, using the radiomics nomogram to predict small cell lung cancer adds more benefit than treating either all or no patients.

will try to increase the sample size and carry out multicenter joint research.

In conclusion, the radiomics signature we established has good performance for the classification of SCLC and NSCLC, and we also developed and validated the first nomogram with better diagnostic performance for the classification of SCLC and NSCLC based on the radiomics signature and clinical factors.

DATA AVAILABILITY STATEMENT

All datasets generated for this study are included in the article/supplementary material.

REFERENCES

1. McGuire S. Switzerland: World Health Organization, International agency for research on cancer, WHO press, 2015. Adv Nutr. (2016) 7:418–9. doi: 10.3945/an.116.012211
2. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers CD, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. (2015) 136:E359–86. doi: 10.1002/ijc.29210
3. Kakinuma R. Low-dose helical CT screening for lung cancer. Jpn J Lung Cancer. (2003) 43:1001–5. doi: 10.2482/haijan.43.1001
4. Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG. Introduction to the 2015 World Health Organization classification of tumors of the lung, pleura, thymus, and heart. J Thorac Oncol. (2015) 10:1240–2. doi: 10.1097/JTO.0000000000000663
5. Ardizzoni A. Topotecan in the treatment of recurrent small cell lung cancer: an update. Oncologist. (2004) 9:4–13. doi: 10.1634/theoncologist.9-90006-4
6. Dieter U. Chemotherapy in stage I+II non-small cell lung cancer. Lung Cancer. (2011) 33:S25–8. doi: 10.1016/S0169-5002(01)00299-9
7. Howington JA, Blum MG, Chang AC, Baledian AA, Murthy SC. Treatment of stage I and II non-small cell lung cancer: diagnosis and management of lung cancer: American college of chest physicians evidence-based clinical practice guidelines. Chest. (2013) 143:e278S–e313S. doi: 10.1378/chest.12-2339
8. Waller DA. Surgery for non-small cell lung cancer—new trends. Lung Cancer. (2011) 74:S133–6. doi: 10.1016/S0169-5002(10)00357-9

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Institutional Review Board of the Affiliated Hospital of Qingdao University.

AUTHOR CONTRIBUTIONS

QF, ShiL, and ShuL conceived the project, analyzed the data, and wrote the paper. HY, YH, and XT participated in data collection and processing. QF, CZ, WX, and XL provided expert guidance and reviewed the manuscript. All authors edited the manuscript. Thanks to Professor Wenhong Wang, Jigang Wang, and Zhimin Wei for their guidance and help in pathology related work.
9. Christian M. Treatment algorithm in 2014 for advanced non-small cell lung cancer: therapy selection by tumour histology and molecular biology. *Adv Med Sci.* (2014) 59:308–13. doi: 10.1016/j.adms.2014.08.008

10. Coufe T, Ovcaric T, O’Brien, Mary ER. Systemic therapy of advanced non-small cell lung cancer: major-developments of the last 5 years. *Eur J Cancer.* (2013) 49:1216–25. doi: 10.1016/j.ejca.2012.11.021

11. Guimarães MD, Marchiori E, Hochhegger B, Chojniak R, Gross JL. CT-guided biopsy of lung lesions: defining the best needle option for a specific diagnosis. *Clinics.* (2014) 69:335–40. doi: 10.6061/clinics/2014(04)0507

12. Aktaş AR, Gözlek E, Yılmaz O, Kayan M, Ünlü N, Demirtaş H, et al. CT-guided transthoracic biopsy: histopathologic results and complication rates. *Diagn Interv Radiol.* (2015) 21:67–70. doi: 10.5152/dir.2014.140140

13. Jad K, Tony A. Interstitial lung disease: the diagnostic role of bronchoscopy. *J Thorac Dis.* (2017) 9:e996–S1010. doi: 10.21037/jtd.2017.06.39

14. Sharafkhanah A, Baaklini W, Gorin AB, Green L. Yield of transthoracic needle aspiration in diagnosis of mediastinal lesions. *Chest.* (2003) 124:2131–35. doi: 10.1378/chest.124.6.2131

15. Wu CC, Maher MM, Shepard JA. Complications of CT-guided percutaneous needle biopsy of the chest: prevention and management. *Am J Roentgenol.* (2011) 196:W678–82. doi: 10.2214/AJR.10.4659

16. Khan MF, Straub R, Moghaddam SR, Maataoui A, Gurung J, Wagner TO, et al. Variables affecting the risk of pneumothorax and intrapulmonary hemorrhage in CT-guided transthoracic biopsy. *Eur Radiol.* (2008) 18:1356–63. doi: 10.1007/s00330-008-0893-1

17. Soler M. Transbronchial needle aspiration and mediastinal staging in lung cancer. *Respiration.* (2003) 70:572–3. doi: 10.1159/000075200

18. Hosny A, Parmar C, Coroller TP, Grossmann P, Zeleznik R, Kumar A. Deep learning for lung cancer prognostication: a retrospective multi-cohort radiomics study. *PLoS Med.* (2018) 15:e1002711. doi: 10.1371/journal.pmed.1002711

19. Kim H, Park CM, Goo JM, Wildberger JE, Kauczor HU. Quantitative analysis of spectral parameters and their correlation with tumor characteristics. *Eur Radiol.* (2018) 11:1398–404. doi: 10.1007/s00330-018-04017

20. Aerts HJ, Velazquez E, Leijenaar R, Parmar C, Grossmann P, Carvalho S, et al. Radiomics-based features for pattern recognition of lung cancer histology and metastases. *Comput Meth Progs Bio.* (2018) 159:23–30. doi: 10.1016/j.cmpb.2018.02.015

21. Zhu X, Dong D, Chen Z, Fang M, Li W, Song J, et al. Radiomic signature as a diagnostic factor for histologic subtype classification of non-small cell lung cancer. *Eur Radiol.* (2018) 7:2272–8. doi: 10.1007/s00330-017-5221-1

22. Linnning E, Lu L, Li L, Yang H, Schwartz LH, Zhao B. Radiomics for classification of lung cancer histological subtypes based on nonenhanced computed tomography. *Acad Radiol.* (2019) 9:1245–52. doi: 10.1016/j.acra.2018.10.013

23. Linnning E, Lu L, Li L, Yang H, Schwartz LH, Zhao B. Radiomics for classifying histological subtypes of lung cancer based on multiphasic contrast-enhanced computed tomography. *J Comput Assist Tomogr.* (2019) 43:300–6. doi: 10.1097/RCT.0000000000000836

24. Cornfield J, Haenszel W, Hammond EC, Lilienfeld MB, Shimkin MB, Wynder EL. Smoking and lung cancer: recent evidence and a discussion of some questions. *Int J Epidemiol.* (2009) 38:1175–91. doi: 10.1093/ije/dyp289

25. Morabia A. Re: smoking and lung cancer: recent evidence and a discussion of some questions. *Int J Epidemiol.* (2010) 39:1676. doi: 10.1093/ije/dyp353

26. Wu F, Zhou H, Li F, Wang JT, Ai T. Spectral CT imaging of lung cancer: quantitative analysis of spectral parameters and their correlation with tumor characteristics. *Acad Radiol.* (2018) 34:2157–64. doi: 10.1016/j.acra.2018.04.017

27. El Naqa I. The role of quantitative PET in predicting cancer treatment outcomes. *Cin Transl Imaging.* (2014) 4:305–20.

28. Gillies RJ, Kinahan PE, Hricak H. Radiomics: images are more than pictures, they are data. *Radiology.* (2016) 278:563–77. doi: 10.1148/radiol.2015111169

29. Cornfield J, Haenszel W, Hammond EC, Lilienfeld MB, Shimkin MB, Wynder EL. Smoking and lung cancer: recent evidence and a discussion of some questions. *Int J Epidemiol.* (2009) 38:1175–91. doi: 10.1093/ije/dyp289

30. Aerts H, Velazquez E, Leijenaar R, Parmar C, Grossmann P, Carvalho S, et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. *Nat Commun.* (2014) 5:4006. doi: 10.1038/ncomms5644

31. Lambin P, Rios-Velazquez E, Leijenaar R, Carvalho S, van Stiphout RG, Granton P, et al. Radiomics: extracting more information from medical images using advanced feature analysis. *Eur J Cancer.* (2012) 48:441–6. doi: 10.1016/j.ejca.2011.11.036

32. Rosado-De-Christenson ML, Templeton PA, Moran CA. Bronchogenic carcinoma: radiologic-pathologic correlation. *Radiographics.* (1994) 14:429–46. doi: 10.1148/radiographics.14.2.8190965

33. Kido S, Kuriyama K, Higashiyama M, Kasugai T, Kuroda C. Fractal analysis in lung adenocarcinoma. *Eur J Cancer.* (2011) 47:1135–40.

34. Parmar C, Leijenaar RT, Grossmann P, Velazquez ER, Bussink J, Rietveld D, et al. Radiomic feature clusters and prognostic signatures specific for lung and head & neck cancer. *Sci Rep.* (2015) 5:11044. doi: 10.1038/srep11044

35. Aerts H, Velazquez E, Leijenaar R, Parmar C, Grossmann P, Carvalho S, et al. CT-based radiomic signature predicts distant metastasis in lung adenocarcinoma. *Radioter Oncol.* (2015) 114:345–50. doi: 10.1016/j.radonc.2015.02.015

36. Wu W, Parmar C, Grossmann P, Quackenbush J, Lambin P, Bussink G, et al. Exploratory study to identify radiomics classifiers for lung cancer histology. *Front Oncol.* (2016) 6:71. doi: 10.3389/fonc.2016.00071

37. Basu S, Hall LO, Goldgof DB, Gu Y, Gatesy RA. Developing a classifier model for lung tumors in CT-scan images[C]. In: *Proceedings of the IEEE International Conference on Systems, Man and Cybernetics* (Anchorage, AK) (2011), p. 1306–12.

38. Junior J, Koenigkam-Santos M, Cipriano F, Fabro A, Azevedo-Marques P. Radiomics-based features for pattern recognition of lung cancer histopathology and metastases. *Comput Meth Progs Bio.* (2018) 159:23–30. doi: 10.1016/j.cmpb.2018.02.015

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Liu, Liu, Zhang, Yu, Liu, Hu, Xu, Tang and Fu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.